Search details
1.
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
J Infect Dis
; 226(4): 595-607, 2022 09 04.
Article
in English
| MEDLINE | ID: mdl-32939546
2.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med
; 19(1): e1003865, 2022 01.
Article
in English
| MEDLINE | ID: mdl-35015777
3.
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
J Infect Dis
; 223(7): 1171-1182, 2021 04 08.
Article
in English
| MEDLINE | ID: mdl-31821493
4.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
PLoS Med
; 18(10): e1003813, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34714820
5.
Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation.
J Virol
; 93(18)2019 09 15.
Article
in English
| MEDLINE | ID: mdl-31243126
6.
A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus.
J Theor Biol
; 495: 110254, 2020 06 21.
Article
in English
| MEDLINE | ID: mdl-32205143
7.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
J Infect Dis
; 220(1): 57-67, 2019 06 05.
Article
in English
| MEDLINE | ID: mdl-30796816
8.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
J Infect Dis
; 220(1): 46-56, 2019 06 05.
Article
in English
| MEDLINE | ID: mdl-30796818
9.
Trypanosoma brucei Co-opts NK Cells to Kill Splenic B2 B Cells.
PLoS Pathog
; 12(7): e1005733, 2016 07.
Article
in English
| MEDLINE | ID: mdl-27403737
10.
Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.
PLoS Pathog
; 12(3): e1005483, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-27032093
11.
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
PLoS Negl Trop Dis
; 18(4): e0011500, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38603720
12.
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Vaccines (Basel)
; 12(5)2024 May 04.
Article
in English
| MEDLINE | ID: mdl-38793748
13.
T. brucei infection reduces B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through transitional B-cell apoptosis.
PLoS Pathog
; 7(6): e1002089, 2011 Jun.
Article
in English
| MEDLINE | ID: mdl-21738467
14.
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
NPJ Vaccines
; 8(1): 174, 2023 Nov 08.
Article
in English
| MEDLINE | ID: mdl-37940656
15.
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.
Vaccines (Basel)
; 10(6)2022 May 31.
Article
in English
| MEDLINE | ID: mdl-35746491
16.
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
PLoS One
; 17(10): e0274906, 2022.
Article
in English
| MEDLINE | ID: mdl-36197845
17.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
NPJ Vaccines
; 7(1): 156, 2022 Nov 30.
Article
in English
| MEDLINE | ID: mdl-36450746
18.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Lancet Infect Dis
; 22(1): 110-122, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34529962
19.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Lancet Infect Dis
; 22(1): 97-109, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34529963
20.
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
NPJ Vaccines
; 6(1): 157, 2021 Dec 20.
Article
in English
| MEDLINE | ID: mdl-34930928